Fulcrum Therapeutics, Inc.
FULC
$6.92
-$0.51-6.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | 3,087.25% | 2,752.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | 3,087.25% | 2,752.05% |
| Cost of Revenue | -25.90% | -108.96% | -108.07% | -102.29% | -93.52% |
| Gross Profit | -104.58% | -37.91% | -18.60% | 212.95% | 209.20% |
| SG&A Expenses | -21.35% | -24.59% | -25.33% | -16.97% | -12.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.09% | -25.41% | -27.70% | -21.44% | -12.02% |
| Operating Income | -327.39% | -187.02% | -152.36% | 90.76% | 82.08% |
| Income Before Tax | -669.97% | -297.00% | -261.84% | 99.49% | 90.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -669.97% | -297.00% | -261.84% | 99.49% | 90.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -669.97% | -297.00% | -261.84% | 99.49% | 90.01% |
| EBIT | -327.39% | -187.02% | -152.36% | 90.76% | 82.08% |
| EBITDA | -357.10% | -200.37% | -163.20% | 91.91% | 83.19% |
| EPS Basic | -498.08% | -305.92% | -266.26% | 97.10% | 87.57% |
| Normalized Basic EPS | -618.79% | -357.99% | -256.30% | 99.16% | 89.65% |
| EPS Diluted | -430.77% | -278.09% | -245.79% | 95.48% | 85.94% |
| Normalized Diluted EPS | -543.03% | -325.95% | -236.63% | 97.96% | 88.44% |
| Average Basic Shares Outstanding | 5.34% | -2.77% | -2.62% | -2.60% | -1.90% |
| Average Diluted Shares Outstanding | 4.74% | -3.31% | -3.16% | -2.04% | -1.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |